Jyoti Patel

Summary

Affiliation: Queen Mary
Country: UK

Publications

  1. ncbi Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice
    Jyoti Patel
    Department of Neuroscience, Barts and The London, Queen Mary s School of Medicine and Dentistry, Queen Mary, University of London, Mile End Road, London E1 4NS, UK
    J Neurochem 85:898-910. 2003
  2. ncbi Assessment of CD24 expression on bone marrow neutrophilic granulocytes: CD24 is a marker for the myelocytic stage of development
    M Tarek Elghetany
    Division of Hematopathology, Department of Pathology, University of Texas Medical Branch, Galveston, Texas 77555 0743, USA melghetautmb edu
    Am J Hematol 71:348-9. 2002
  3. ncbi Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma
    Faye M Johnson
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77230-1402, USA
    Cancer 106:366-74. 2006

Collaborators

Detail Information

Publications3

  1. ncbi Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice
    Jyoti Patel
    Department of Neuroscience, Barts and The London, Queen Mary s School of Medicine and Dentistry, Queen Mary, University of London, Mile End Road, London E1 4NS, UK
    J Neurochem 85:898-910. 2003
    ....
  2. ncbi Assessment of CD24 expression on bone marrow neutrophilic granulocytes: CD24 is a marker for the myelocytic stage of development
    M Tarek Elghetany
    Division of Hematopathology, Department of Pathology, University of Texas Medical Branch, Galveston, Texas 77555 0743, USA melghetautmb edu
    Am J Hematol 71:348-9. 2002
    ..We conclude that CD24 is expressed on the neutrophilic granulocytes at the stage of myelocytes, and hence it could potentially be used to study normal and abnormal maturation of granulocytes...
  3. ncbi Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma
    Faye M Johnson
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77230-1402, USA
    Cancer 106:366-74. 2006
    ..The decreased irinotecan clearance may explain the high incidence of diarrhea and neutropenia noted in the current study...